Jennie L. Conroy - Publications

Albany Medical Center, Albany, NY, United States 
Pain research

11 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 Dix AV, Conroy JL, George Rosenker KM, Sibley DR, Appella DH. PNA-Based Multivalent Scaffolds Activate the Dopamine D2 Receptor. Acs Medicinal Chemistry Letters. 6: 425-9. PMID 25893044 DOI: 10.1021/Ml500478M  0.6
2015 Conroy JL, Free RB, Sibley DR. Identification of G protein-biased agonists that fail to recruit β-arrestin or promote internalization of the D1 dopamine receptor. Acs Chemical Neuroscience. 6: 681-92. PMID 25660762 DOI: 10.1021/Acschemneuro.5B00020  0.6
2015 Meade JA, Free RB, Miller NR, Chun LS, Doyle TB, Moritz AE, Conroy JL, Watts VJ, Sibley DR. (-)-Stepholidine is a potent pan-dopamine receptor antagonist of both G protein- and β-arrestin-mediated signaling. Psychopharmacology. 232: 917-30. PMID 25231919 DOI: 10.1007/S00213-014-3726-8  0.6
2014 Free RB, Chun LS, Moritz AE, Miller BN, Doyle TB, Conroy JL, Padron A, Meade JA, Xiao J, Hu X, Dulcey AE, Han Y, Duan L, Titus S, Bryant-Genevier M, et al. Discovery and characterization of a G protein-biased agonist that inhibits β-arrestin recruitment to the D2 dopamine receptor. Molecular Pharmacology. 86: 96-105. PMID 24755247 DOI: 10.1124/Mol.113.090563  0.6
2014 Xiao J, Free RB, Barnaeva E, Conroy JL, Doyle T, Miller B, Bryant-Genevier M, Taylor MK, Hu X, Dulcey AE, Southall N, Ferrer M, Titus S, Zheng W, Sibley DR, et al. Discovery, optimization, and characterization of novel D2 dopamine receptor selective antagonists. Journal of Medicinal Chemistry. 57: 3450-63. PMID 24666157 DOI: 10.1021/Jm500126S  0.6
2013 Conroy JL, Nalwalk JW, Phillips JG, Hough LB. CC12, a P450/epoxygenase inhibitor, acts in the rat rostral, ventromedial medulla to attenuate morphine antinociception. Brain Research. 1499: 1-11. PMID 23298831 DOI: 10.1016/J.Brainres.2012.12.030  0.6
2013 Bergman J, Roof RA, Furman CA, Conroy JL, Mello NK, Sibley DR, Skolnick P. Modification of cocaine self-administration by buspirone (buspar®): potential involvement of D3 and D4 dopamine receptors. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 16: 445-58. PMID 22827916 DOI: 10.1017/S1461145712000661  0.6
2013 Free RB, Conroy JL, Roof RA, Doyle T, Han Y, Donthamsetti P, Javitch JA, Southall N, Emmitte K, Lindsley C, Ferrer M, Sibley DR. High-Throughput Screening for Modulators of the D2 Dopamine Receptor Yields Unique and Selective Pharmacological Chemotypes Catecholamine Research in the 21st Century: Abstracts and Graphical Abstracts, 10th International Catecholamine Symposium, 2012. 115. DOI: 10.1016/B978-0-12-800044-1.00101-X  0.6
2013 Conroy JL, Free RB, Doyle TB, Sibley DR. Identification of Substituted Benzazepines as Functionally Selective Ligands of the D1 Dopamine Receptor Catecholamine Research in the 21st Century: Abstracts and Graphical Abstracts, 10th International Catecholamine Symposium, 2012. 113. DOI: 10.1016/B978-0-12-800044-1.00099-4  0.6
2011 Hough LB, Nalwalk JW, Yang J, Conroy JL, VanAlstine MA, Yang W, Gargano J, Shan Z, Zhang SZ, Wentland MP, Phillips JG, Knapp BI, Bidlack JM, Zuiderveld OP, Leurs R, et al. Brain P450 epoxygenase activity is required for the antinociceptive effects of improgan, a nonopioid analgesic. Pain. 152: 878-87. PMID 21316152 DOI: 10.1016/J.Pain.2011.01.001  0.6
2010 Conroy JL, Fang C, Gu J, Zeitlin SO, Yang W, Yang J, VanAlstine MA, Nalwalk JW, Albrecht PJ, Mazurkiewicz JE, Snyder-Keller A, Shan Z, Zhang SZ, Wentland MP, Behr M, et al. Opioids activate brain analgesic circuits through cytochrome P450/epoxygenase signaling. Nature Neuroscience. 13: 284-6. PMID 20139973 DOI: 10.1038/Nn.2497  0.6
Show low-probability matches.